OrthoPediatrics preliminary Q3 rev $61.2M (+12% YoY); cuts FY guidance to $233.5-$234.5M

ORTHOPEDIATRICS CORP

2025-Q3 EPS reported -$1.26 revenue$174,743,000

Preliminary Q3 net revenue $61.2M, up 12% YoY; domestic $48.7M (+14%), international $12.5M (+6%).
Revenue excluding 7D capital sales $60.7M, up 17% YoY; capital sales delayed late in quarter.
FY2025 revenue guidance lowered to $233.5-$234.5M from $237-$242M; growth 14-15% YoY.
Reiterated $15M set deployment and adjusted EBITDA guidance of $15-$17M.
Headwinds: delayed 7D capital orders and Latin/South America order timing variability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.